Switch theme
Sign up to access all valuation multiples
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.
1996
n/a
LTM Revenue $62.0M
LTM EBITDA $11.4M
$86.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Meditera has a last 12-month revenue (LTM) of $62.0M and a last 12-month EBITDA of $11.4M.
In the most recent fiscal year, Meditera achieved revenue of $52.6M and an EBITDA of $5.9M.
Meditera expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Meditera valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $62.0M | XXX | $52.6M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $20.8M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 40% | XXX | XXX | XXX |
| EBITDA | $11.4M | XXX | $5.9M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 11% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $6.2M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $2.2M | XXX | $1.8M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Meditera's stock price is TRY 32 (or $1).
Meditera has current market cap of TRY 3.8B (or $95.0M), and EV of TRY 3.4B (or $86.3M).
See Meditera trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $86.3M | $95.0M | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Meditera has market cap of $95.0M and EV of $86.3M.
Meditera's trades at 1.6x EV/Revenue multiple, and 14.7x EV/EBITDA.
Equity research analysts estimate Meditera's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Meditera has a P/E ratio of 42.7x.
See valuation multiples for Meditera and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $95.0M | XXX | $95.0M | XXX | XXX | XXX |
| EV (current) | $86.3M | XXX | $86.3M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 7.6x | XXX | 14.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 14.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 42.7x | XXX | 51.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 8.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMeditera's last 12 month revenue growth is 32%
Meditera's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Meditera's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Meditera's rule of X is 99% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Meditera and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 32% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 47% | XXX | 81% | XXX | XXX | XXX |
| Rule of 40 | 43% | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 99% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Meditera acquired XXX companies to date.
Last acquisition by Meditera was XXXXXXXX, XXXXX XXXXX XXXXXX . Meditera acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Meditera founded? | Meditera was founded in 1996. |
| Where is Meditera headquartered? | Meditera is headquartered in Turkey. |
| Is Meditera publicy listed? | Yes, Meditera is a public company listed on IST. |
| What is the stock symbol of Meditera? | Meditera trades under MEDTR ticker. |
| When did Meditera go public? | Meditera went public in 2021. |
| Who are competitors of Meditera? | Similar companies to Meditera include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Meditera? | Meditera's current market cap is $95.0M |
| What is the current revenue of Meditera? | Meditera's last 12 months revenue is $62.0M. |
| What is the current revenue growth of Meditera? | Meditera revenue growth (NTM/LTM) is 32%. |
| What is the current EV/Revenue multiple of Meditera? | Current revenue multiple of Meditera is 1.4x. |
| Is Meditera profitable? | Yes, Meditera is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Meditera? | Meditera's last 12 months EBITDA is $11.4M. |
| What is Meditera's EBITDA margin? | Meditera's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Meditera? | Current EBITDA multiple of Meditera is 7.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
